Treatment Clinical Trials for Melanoma

Clinical trials are research studies that involve people. The clinical trials on this list are for melanoma treatment. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 76-100 of 261

  • Nivolumab with or without Ipilimumab in Treating Patients with Advanced or Metastatic Melanoma or Bladder Cancer

    This phase II trial studies how well nivolumab works with or without ipilimumab in treating patients with melanoma or bladder cancer that has spread to other places in the body or has spread from the primary site to other places in the body. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
    Location: 4 locations

  • Dabrafenib, Trametinib and Hydroxychloroquine in Treating Patients with Stage IV Metastatic Melanoma

    This phase I / II trial studies the side effects and best dose of hydroxychloroquine when given together with dabrafenib and trametinib and to see how well they work in treating patients with stage IV melanoma that has spread to other places in the body. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Sometimes when dabrafenib and trametinib are given, the tumor cells activate a stress response called autophagy. Autophagy provides resistance to dabrafenib and trametinib treatment over time making them less effective. Giving hydroxychloroquine with dabrafenib and trametinib may reduce drug resistance and allow more tumor cells to be killed.
    Location: 4 locations

  • Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902 / E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003 / E7080-G000-312 / LEAP-003)

    The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902 / E7080) compared to pembrolizumab alone (with placebo for lenvatinib) as first-line treatment in adults with no prior systemic therapy for their advance melanoma. The primary study hypotheses are that: 1) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Progression-free Survival (PFS) per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1), and 2) The combination of pembrolizumab and lenvatinib is superior to pembrolizumab and placebo as assessed by Overall Survival (OS). For this study, RECIST 1.1 has been modified to follow a maximum of 10 target lesions and a maximum of 5 target lesions per organ.
    Location: 4 locations

  • Intratumoral AST-008 Combined With Pembrolizumab in Patients With Advanced Solid Tumors

    This is a phase 1b / 2, open-label, multicenter trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary efficacy of intratumoral AST-008 injections alone and in combination with intravenous pembrolizumab in patients with advanced solid tumors. Phase 1b of this trial is a 3+3 dose escalation study evaluating escalating or intermediate dose levels of AST-008 given with a fixed dose of pembrolizumab. Phase 2 is an expansion cohort to further evaluate AST-008 given in combination with pembrolizumab in a specific population to provide a preliminary estimate of efficacy in patients who have previously received and not responded to anti-PD-1 or anti-PD-L1 antibody therapy.
    Location: 4 locations

  • Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

    A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel) / LN-145 in combination with pembrolizumab. TIL as a single-therapy will be evaluated with LN-145 only.
    Location: 5 locations

  • Study of Efficacy and Safety of Novel Spartalizumab Combinations in Patients With Previously Treated Unresectable or Metastatic Melanoma

    The primary purpose of this study is to evaluate the efficacy of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma
    Location: 5 locations

  • Ensartinib in Treating Patients with Advanced Melanoma Harboring ALK Alterations

    This phase II trial studies how well ensartinib works in treating patients with melanoma that has spread to other places in the body or is no longer responding to treatment and has proteins called ALK that are abnormal. Ensartinib may stop the growth of tumor cells by blocking the ALK proteins, which are needed for cell growth.
    Location: 3 locations

  • A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Malignancies

    This is a study to determine the maximum tolerated dose (MTD) for CDX-1140, either alone or in combination with CDX-301, and to further evaluate its tolerability and efficacy in expansion cohorts once the MTD is determined.
    Location: 4 locations

  • Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects With Resected Solid Tumors and in Combination With Pembrolizumab in Subjects With Unresectable Solid Tumors

    The purpose of this study is to assess the safety, tolerability and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors, and in combination with pembrolizumab in subjects with unresectable solid tumors.
    Location: 3 locations

  • Pembrolizumab and Trebananib in Treating Patients with Solid Tumors That Are Advanced, Metastatic, or Cannot Be Removed by Surgery

    This phase Ib trial studies side effects and best dose of trebananib when given with pembrolizumab in treating patients with solid tumors that have spread to other places or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trebananib may kill tumor cells by blocking blood vessels that supply the tumor with nutrients and oxygen. Giving pembrolizumab and trebananib may work better in treating patients with solid tumors.
    Location: 3 locations

  • Pembrolizumab and Trametinib with or without Dabrafenib in Treating Patients with Melanoma That Is Metastatic or Cannot Be Removed by Surgery

    This phase II trial studies how well pembrolizumab and trametinib with or without dabrafenib work in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body’s immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Trametinib and dabrafenib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving pembrolizumab and trametinib with or without dabrafenib may work better in treating patients with melanoma.
    Location: 3 locations

  • Tavo and Pembrolizumab in Patients With Stage III / IV Melanoma Progressing on Pembrolizumab or Nivolumab Treatment

    This will be a Phase 2 study of intratumoral tavokinogene telseplasmid (tavo; pIL-12) Electroporation (EP) plus IV Pembrolizumab. Eligible patients will be those with pathological diagnosis of unresectable or metastatic melanoma who are progressing or have progressed on pembrolizumab or nivolumab.
    Location: 3 locations

  • A Phase 1 / 2 Safety Study of Intratumorally Dosed INT230-6

    This study evaluates the intratumoral administration of escalating doses of a novel, experimental drug, INT230-6. The study is being conducted in patients with several types of refractory cancers including those at the surface of the skin (melanoma, head and neck, lymphoma, breast) and tumors within the body such (pancreatic, colon, liver, lung, etc.). Sponsor also plans to test INT230-6 in combination with anti-PD-1 antibodies.
    Location: 3 locations

  • Study in Subjects With Small Primary Choroidal Melanoma

    The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.
    Location: 3 locations

  • Phenformin Hydrochloride, Dabrafenib, and Trametinib in Treating Patients with Stage III-IV BRAF V600E / K-Mutated Melanoma

    This phase I trial studies the side effects and best dose of phenformin hydrochloride when given together with dabrafenib and trametinib in treating patients with stage III-IV BRAF V600E / K-mutated melanoma. Phenformin hydrochloride may work by shrinking the tumors. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving phenformin hydrochloride, dabrafenib, and trametinib may work better at treating melanoma and might prevent the tumor from becoming resistant to treatment.
    Location: 3 locations

  • A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade

    This is a multi center, phase I pilot study of sequential ONCOS-102 and pembrolizumab in patients with advanced or unresectable melanoma progressing after PD1 blockade. The primary objective of the study is to determine the safety of sequential treatment with ONCOS-102 followed by pembrolizumab. The protocol aims to enroll patients into two cohorts: Part I: up to 12 patients will receive sequential treatment with ONCOS-102 followed by pembrolizumab. Part II: up to 12 patients will receive an initial treatment phase with ONCOS-102 followed by a treatment phase with ONCOS-102 in combination with pembrolizumab.
    Location: 3 locations

  • A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma

    To characterize safety and tolerability and identify a recommended dose and regimen for the LXH254 in combination with LTT462 or trametinib or ribociclib.
    Location: 4 locations

  • Talimogene Laherparepvec with or without Hypofractionated Radiation Therapy in Treating Patients with Metastatic Melanoma, Merkel Cell Carcinoma, or Other Solid Tumors

    This randomized phase II trial studies the side effects of talimogene laherparepvec and to see how well it works with or without hypofractionated radiation therapy in treating patients with skin melanoma, Merkel cell carcinoma, or other solid tumors that have spread to places not suitable for surgical removal. Drugs used in the immunotherapy, such as talimogene laherparepvec, may stimulate the body's immune system to fight tumor cells. Hypofractionated radiation therapy delivers higher doses of radiation therapy over a shorter period of time and may kill more tumor cells and have fewer side effects. It is not yet known if giving talimogene laherparepvec with or without hypofractionated radiation therapy will work better in treating patients with cutaneous melanoma, Merkel cell carcinoma, or solid tumors.
    Location: 3 locations

  • Phase Ib / II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

    The purpose of this study of MCS110 with PDR001 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the combination of MCS110 with PDR001 in adult patients with solid tumors.
    Location: 4 locations

  • Selumetinib Sulfate in Treating Patients with Uveal Melanoma or GNAQ / GNA11 Mutated Melanoma That Is Metastatic or Cannot Be Removed by Surgery

    This phase Ib trial studies the side effects and best dose of selumetinib sulfate in treating patients with uveal melanoma or GNAQ / GNA11 mutated melanoma that has spread from the primary site to other places in the body or cannot be removed by surgery. Selumetinib sulfate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • Study of HBI-8000 With Nivolumab in Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer

    A Phase 1b / 2 Study to Assess the Safety and Efficacy of HBI-8000 in Combination with Nivolumab in Patients with Advanced Solid Tumors Including Melanoma, Renal Cell Carcinoma (RCC), and Non-Small Cell Lung Cancer (NSCLC). The primary objective of this study is: -To evaluate the safety and tolerability of HBI-8000 when combined with a standard dose and regimen of nivolumab, to determine Maximum Tolerated Dose (MTD) and / or Recommended Phase 2 Dose (RP2D) and to evaluate frequency and severity of toxicities of this combination treatment The secondary objectives of this study include: - To explore the efficacy of study treatment as measured by Objective Response Rate (ORR), Disease Control Rate (DCR), Clinical Benefit Rate (CBR), Duration of Response (DoR), Progression-Free Survival (PFS) in all subjects treated at RP2D - To obtain pharmacokinetics of twice weekly HBI-8000 when administered in combination with nivolumab administered once every two weeks (Phase 1b all sites; Phase 2 selected sites) - To characterize the effect of HBI-8000 on the electrocardiogram QT corrected (QTc) interval (Phase 1b only) Exploratory: -To investigate the kinetics and extent of histone acetylation in peripheral blood mononuclear cells (PBMC) at the RP2D of HBI-8000 (Phase 2 only) Dose Escalation (Phase 1b) will include up to 18 subjects, followed by Cohort Expansion (Phase 2) including up to 20 subjects per tumor indication at MTD and / or RP2D (including those treated in Phase 1b).
    Location: 3 locations

  • Phase I Study of LXH254 in Patients With Advanced Solid Tumors Haboring MAPK Pathway Alterations

    A Phase I Study of LXH254 in Patients With Advanced Solid Tumors That Harbor MAPK Pathway Alterations.
    Location: 3 locations

  • Trial to Evaluate the Safety ofTalimogene Laherparepvec Injected Into Liver Tumors Alone and in Combination With Systemic Pembrolizumab

    This is a phase 1b / 2, multicenter, open-label trial to evaluate the safety of talimogene laherparepvec injected intrahepatically into liver tumors with known progression alone and in combination with systemic IV administration of pembrolizumab, in subjects with non-HCC liver metastases from BC, CRC, GEC, melanoma, NSCLC, RCC, and subjects with HCC. The study consists of 2 parts and 2 groups, and Part 2 includes 2 stages. The objective of Part 1 is to evaluate the safety of intrahepatic injection of talimogene laherparepvec into liver tumors alone and in combination with systemically administered pembrolizumab for the non-HCC (Group A) and HCC (Group B) cohorts separately. Part 2 consists of 2-stage design to evaluate the efficacy and safety of talimogene laherparepvec in combination with systemic pembrolizumab. Efficacy and safety will be evaluated in each of the six non-HCC tumor types from Group A separately. Similarly, the efficacy and safety of the combination treatment will be determined for Group B HCC subjects.
    Location: 5 locations

  • Trametinib in Treating Patients with Advanced Melanoma with BRAF Non-V600 Mutations

    This phase II trial studies trametinib in treating patients with melanoma with v-Raf murine sarcoma viral oncogene homolog B (BRAF) non-V600 mutations that has spread to other places in the body. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
    Location: 3 locations

  • A Phase 1 Multiple Ascending Dose Study of DS-3032b, an Oral Murine Double Minute 2 (MDM2) Inhibitor, in Subjects With Advanced Solid Tumors or Lymphomas

    This will be a Phase 1, open-label study of DS-3032b to assess its safety and tolerability, identify a maximum tolerated dose (MTD) / tentative recommended phase 2 dose (RP2D), and assess its pharmacokinetic (PK) / pharmacodynamic (PD) properties in subjects with advanced solid tumors or lymphomas. Approximately 5 US sites are planned for Part 1 (Dose Escalation). Approximately 10 US sites are planned for Part 2 (Dose Expansion).
    Location: 3 locations